Evrópusambandið - íslenska - EMA (European Medicines Agency)

astrazeneca ab - olaparib - Æxli í eggjastokkum - Æxlishemjandi lyf - blöðrur á cancerlynparza er ætlað eitt og sér fyrir:viðhald meðferð fullorðinn sjúklinga með langt (figo stigum iii og iv) brca1/2-stökkbreytt (germline og/eða líkamsvöxt) hágæða þekju blöðrur, eggjaleiðara eða aðal kviðarholi krabbamein sem eru í svar (heill eða hluta) eftir að ljúka fyrsta lína platínu-byggt lyfjameðferð. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy. lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability (see section 5. breast cancerlynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline brca1/2-mutations who have her2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4. 2 og 5. monotherapy for the treatment of adult patients with germline brca1/2-mutations, who have her2 negative locally advanced or metastatic breast cancer. sjúklingar að hefur áður verið meðhöndluð með anthracycline og taxane í (neo)viðbótar eða sjúklingum setja nema sjúklinga sem voru ekki henta til þessara meðferða (sjá kafla 5. sjúklingar með hormón viðtaka (hr)-jákvæð brjóstakrabbamein ætti líka að hafa gengið á eða eftir áður en annarra meðferð, eða að vera talin óhæf til annarra meðferð. adenocarcinoma of the pancreaslynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline brca1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. prostate cancerlynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mcrpc in whom chemotherapy is not clinically indicated (see section 5.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

stada arzneimittel ag - dronedaronum hýdróklóríð - filmuhúðuð tafla - 400 mg

Evrópusambandið - íslenska - EMA (European Medicines Agency)

secura bio limited - duvelisib - leukemia, lymphocytic, chronic, b-cell; lymphoma, follicular - Æxlishemjandi lyf - copiktra monotherapy is indicated for the treatment of adult patients with: relapsed or refractory chronic lymphocytic leukaemia (cll) after at least two prior therapies.  follicular lymphoma (fl) that is refractory to at least two prior  systemic therapies.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley with subfirm xiromed - atorvastatin kalsíum tríhýdrat - filmuhúðuð tafla - 80 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley with subfirm xiromed - atorvastatin kalsíum tríhýdrat - filmuhúðuð tafla - 20 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

krka sverige ab - fluconazolum inn - hart hylki - 150 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

stada arzneimittel ag - atorvastatin kalsíum tríhýdrat - filmuhúðuð tafla - 10 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

bluefish pharmaceuticals ab - simvastatinum inn - filmuhúðuð tafla - 40 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley with subfirm xiromed - atorvastatin kalsíum tríhýdrat - filmuhúðuð tafla - 10 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley with subfirm xiromed - atorvastatin kalsíum tríhýdrat - filmuhúðuð tafla - 40 mg